Skip to main content
Erschienen in: BMC Infectious Diseases 1/2022

Open Access 01.12.2022 | Case report

Skin infection by Mycobacterium farcinogenessenegalense group in an immunocompetent patient: a case report

verfasst von: An-Yu Cheng, Chih-Hung Lee

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2022

Abstract

Background

Mycobacterium farcinogenessenegalense group mostly cause bovine farcy, which rarely infect human beings. We reported one case of cutaneous Mycobacterium farcinogenessenegalense group infection in an immunocompetent victim.

Case presentation

A 66-year-old Taiwanese woman with hypertension developed tender nodules on her left dorsal foot for 2 months. Tissue culture identified Mycobacterium farcinogenessenegalense group. The lesion was treated successfully with clarithromycin and sulfamethoxazole/trimethoprim, followed by surgical excision.

Conclusions

Mycobacterium farcinogenessenegalense group infection should be considered as a potential pathogen of skin infection in immunocompetent patients.
Hinweise

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Background

Mycobacterium farcinogenes–senegalense group is rapidly growing, non-tuberculous mycobacterium that causes bovine farcy. Mostly documented in sub-Saharan Africa, Mycobacterium farcinogenes and Mycobacterium senegalense result in chronic suppurative granulomas of skin and lymphatics in cattle. They are closely related to Mycobacterium fortuitum and Mycobacterium houstonense. In fact, Mycobacterium farcinogenes–senegalense group rarely affects human beings. [1]

Case presentation

A 66-year-old Taiwanese woman, who was free from immunocompromised conditions including diabetes mellitus or acquired immunodeficiency syndrome, developed enlarging tender nodules on her left dorsal foot for 2 months. Two months prior to this presentation, her left dorsal foot was traumatized by the spring of a trashed mattress. Physical exam showed reddened, indurated, and confluent nodules with pus discharge (Fig. 1). She was afebrile and she denied other constitutional symptoms. She initially tried acupuncture on the left lower leg for but failed. 10 days of empirical oral amoxicillin clavulanate (Augmentin® 1250 mg/day) were administered after the sampling of the pus. Though the culture turned out to be negative, the lesion deteriorated. To exclude atypical infection, we performed skin biopsy for pathology exam, as well as fungal and mycobacterial culture.
Microscopically, skin specimen demonstrated dermal suppurative granulomas composed of histiocytes and multinucleated giant cells. A few acid-fast bacilli were identified by Ziehl–Neelsen stain. 14 days after the culture, wheat-colored colonies developed (Fig. 2). Using Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS; Bruker’s MALDI Biotyper, Bruker Libraries/Mycobacteria Library V2.0) to compare the extracted proteins from the colony to the reference, we successfully identified the pathogen to be the Mycobacterium farcinogenes–senegalense group (MS score 1.94; MS score 1.800–1.999 for species level for mycobacteria). After confirming the pathogen, the antibacterial regimens, featuring the combination of oral clarithromycin (1000 mg/day) and sulfamethoxazole/trimethoprim (Baktar®, 1960 mg/day), were administered for 2 months. Nevertheless, sulfamethoxazole/trimethoprim was held 2 weeks later due to hyperkalemia. The skin lesion resolved gradually thereafter and the residual lesion was eventually cured by surgical removal (Fig. 1d).

Discussion and conclusions

MALDI-TOF MS detects the bacterial protein profile and identifies organisms based on database. It provides simple, fast, and reliable identification in most Mycobacterium species and is a potential alternative laboratory method in routine clinical care [2, 3].
We report a human skin infection by Mycobacterium farcinogenes–senegalense, which usually causes bovine farcy, in an immunocompetent woman after traumatic injury by rusty springs. The first human victim of Mycobacterium senegalense was a 49-year-old woman with non-Hodgkin’s lymphoma in Korea due to catheter-related bloodstream infection [4]. An immunocompetent 67-year-old man in Hong Kong had prosthetic infection of Mycobacterium farcinogenes after receiving total hip arthroplasty [5]. An immunocompetent 3-year-old North American girl got soft tissue infection of Mycobacterium senegalense after traumatic injury [6]. A North American 55-year-old immunocompetent male developed chronic osteomyelitis of Mycobacterium senegalense after traumatic ankle fracture [7]. Some following cases of osteomyelitis related to Mycobacterium farcinogenes were reported. [8, 9]. We summarized the above-mentioned cases in Table 1. We reported an immunocompetent case of Mycobacterium farcinogenes–senegalense group soft tissue infection in Asia, indicating that the infection is worldwide and not limited to immunocompromised patients. Due to its rarity, the consensus of the standard treatment is lacking. Treatment may include amikacin, cefoxitin, clarithromycin, ciprofloxacin, doxycycline, erythromycin, imipenem, trimethoprim/sulfamethoxazole, which is similar to the regimens for rapidly growing mycobacterium. Drug sensitivity test could be beneficial. Surgical excision could be considered in localized lesion in immunocompetent hosts.
Table 1
Cases of Mycobacterium farcinogenessenegalense group
 
Age/sex
Immune state
Country
Species
Infection site
trauma
Treatment course
Oh et al. [4]
49/F
Immunocompromised (non-Hodgkin’s lymphoma)
Korea
M. senegalense
Blood stream (catheter related)
None
Imipenem/cilastatin and amikacin then ciprofloxacin and doxycycline for 4 weeks
Wong et al. [5]
67/F
Immunocompetent
Hong Kong
M. farcinogenes
Prosthetic joint
Toal hip arthroplasty
Surgical removal of implant and debridement; ciprofloxacin and doxycycline intravenously for 6 weeks and then orally for 3 months
Talavlikar et al. [6]
3/F
Immunocompetent
America
M. senegalense
Soft tissue
Fish tank
Clarithromycin, trimethoprim/sulfamethoxazole and ciprofloxacin for 3 months
Maupin et al. [7]
55/M
Immunocompetent
America
M. senegalense
Bone
Traumatic ankle fracture (motor vehicle collision: from the driver’s seat into a pasture ditch)
Surgical removal of implant and debridement; imipenem, ciprofloxacin, and minocycline for 6 weeks, then imipenem, linezolid and azithromycin for 3 months, then linezolid, azithromycin, and doxycycline for another 3 months
Al Farsi et al.  [8]
49/M
Immunocompromised (diabetes mellitus)
Oman
M. farcinogenes
Bone
Anterior cruciate ligament and medial meniscal repair
Surgical removal of implant and debridement; ciprofloxacin and doxycycline for 6 months
Kashihara et al. [9]
37/M
Immunocompetent
Japan
M. farcinogenes
Bone
Traumatic tibia and fibula fracture (concrete)
Surgical debridement; levofloxacin, amikacin, and rifampin for 12 months
Our case (2022)
66/F
Immunocompetent
Taiwan
M. farcinogenessenegalense group
Skin
Trashed mattress
Clarithromycin and sulfamethoxazole/trimethoprim for 2 months followed by surgical excision (sulfamethoxazole/trimethoprim was discontinued at 2 weeks due to intolerance)
The conventional method in isolating bacterial strains from the tissue allows in vitro drug susceptibility test which is useful for clinical decision making. Using the MALDI-TOF method, we could only identify the strain as Mycobacterium farcinogenessenegalense group. However, due to the institutional biosafety regulation, the sample was disposed once the lab data of MALDI-TOF was obtained. Therefore, we could not perform the drug susceptibility test at this point. Furthermore, the current database does not allow us to distinguish the species of these two closely related Mycobacterium farcinogenes and Mycobacterium senegalense.
In conclusion, we reported one rare Mycobacterium farcinogenes–senegalense group cutaneous infection in an immunocompetent patient in Taiwan. The lesion was partially resolved after 2 months of clarithromycin and finally cured by the surgical removal of the remaining. Mycobacterium farcinogenes–senegalense group infection should be considered as potential pathogen of skin infection.

Acknowledgements

We would like to thank Shu-shen Cheng for assisting with culture and species identification.

Declarations

The study is approved by Chang Gung Medical Foundation Institutional Review Board. (No. 202101349B0)
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Hamid ME. Current perspectives on Mycobacterium farcinogenes and Mycobacterium senegalense, the causal agents of bovine farcy. Vet Med Int. 2014;2014:247906.CrossRef Hamid ME. Current perspectives on Mycobacterium farcinogenes and Mycobacterium senegalense, the causal agents of bovine farcy. Vet Med Int. 2014;2014:247906.CrossRef
2.
Zurück zum Zitat Neuschlova M, Vladarova M, Kompanikova J, Sadlonova V, Novakova E. Identification of Mycobacterium species by MALDI-TOF mass spectrometry. Adv Exp Med Biol. 2017;1021:37–42.CrossRef Neuschlova M, Vladarova M, Kompanikova J, Sadlonova V, Novakova E. Identification of Mycobacterium species by MALDI-TOF mass spectrometry. Adv Exp Med Biol. 2017;1021:37–42.CrossRef
3.
Zurück zum Zitat Rychert JA. Benefits and limitations of MALDI-TOF mass spectrometry for the identification of microorganisms. J Infectiol. 2019;2:1–5.CrossRef Rychert JA. Benefits and limitations of MALDI-TOF mass spectrometry for the identification of microorganisms. J Infectiol. 2019;2:1–5.CrossRef
4.
Zurück zum Zitat Oh WS, Ko KS, Song JH, Lee MY, Ryu SY, Taek S, et al. Catheter-associated bacteremia by Mycobacterium senegalense in Korea. BMC Infect Dis. 2005;5:107.CrossRef Oh WS, Ko KS, Song JH, Lee MY, Ryu SY, Taek S, et al. Catheter-associated bacteremia by Mycobacterium senegalense in Korea. BMC Infect Dis. 2005;5:107.CrossRef
5.
Zurück zum Zitat Wong TC, Chan WF, Tsang WL, Yeung SH, Ip FK. Mycobacterium farcinogenes infection after total hip arthroplasty. J Arthroplasty. 2005;20:684–7.CrossRef Wong TC, Chan WF, Tsang WL, Yeung SH, Ip FK. Mycobacterium farcinogenes infection after total hip arthroplasty. J Arthroplasty. 2005;20:684–7.CrossRef
6.
Zurück zum Zitat Talavlikar R, Carson J, Meatherill B, Desai S, Sharma M, Shandro C, et al. Mycobacterium senegalense tissue infection in a child after fish tank exposure. Can J Infect Dis Med Microbiol. 2011;22:101–3.CrossRef Talavlikar R, Carson J, Meatherill B, Desai S, Sharma M, Shandro C, et al. Mycobacterium senegalense tissue infection in a child after fish tank exposure. Can J Infect Dis Med Microbiol. 2011;22:101–3.CrossRef
7.
Zurück zum Zitat Maupin J, Cantrell A, Kupiec K, Melendez DP, Haleem AM. Mycobacterium senegalense osteomyelitis of the distal tibia: a case report. J Bone Joint Infect. 2019;4:140–5.CrossRef Maupin J, Cantrell A, Kupiec K, Melendez DP, Haleem AM. Mycobacterium senegalense osteomyelitis of the distal tibia: a case report. J Bone Joint Infect. 2019;4:140–5.CrossRef
8.
Zurück zum Zitat Al Farsi F, Al Adawi B, Ba Tahir H, Al Mutani M, Adikaram C, Al Siyabi T, et al. Mycobacterium farcinogenes osteomyelitis of the proximal tibia: a case report. IDCases. 2021;25:e01194.CrossRef Al Farsi F, Al Adawi B, Ba Tahir H, Al Mutani M, Adikaram C, Al Siyabi T, et al. Mycobacterium farcinogenes osteomyelitis of the proximal tibia: a case report. IDCases. 2021;25:e01194.CrossRef
9.
Zurück zum Zitat Kashihara E, Fujita K, Yamamoto H, Odagaki T. Mycobacterium farcinogenes infection after fracture repair of the tibia and fibula. IDCases. 2022;28:e01468.CrossRef Kashihara E, Fujita K, Yamamoto H, Odagaki T. Mycobacterium farcinogenes infection after fracture repair of the tibia and fibula. IDCases. 2022;28:e01468.CrossRef
Metadaten
Titel
Skin infection by Mycobacterium farcinogenes–senegalense group in an immunocompetent patient: a case report
verfasst von
An-Yu Cheng
Chih-Hung Lee
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2022
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07409-z

Weitere Artikel der Ausgabe 1/2022

BMC Infectious Diseases 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.